Last updated November 10, 2026
Our verdict
GLP-3RT Vial is our top pick in the weight category. The molecule posted the largest average result of the three GLP-1 generations in its own trials, the store documents 13 lots with outside lab certificates, and the 40 mg size brings the price down to $7.50 per mg. The trade-off is a shorter published record than the dual agonist and no regulatory decision yet.
Scored by our editors against fixed criteria. This is an editorial rating, not an average of customer reviews.
Specifications
| Class | GLP-1 / GIP / glucagon triple agonist |
|---|---|
| Also listed as | LY3437943 |
| Form | Lyophilized powder, 10 mL vial |
| Purity | 99%+ (HPLC) |
| Third-party lab | AxisPharm, LLC |
| Lots with COA | 13 |
Price per mg
| Size | Price | Per mg | 2+ units (5% off) | 5+ units (10% off) |
|---|---|---|---|---|
| 10 mg | $100.00 | $10.00 | $95.00 | $90.00 |
| 20 mg | $170.00 | $8.50 | $161.50 | $153.00 |
| 40 mg | $300.00 | $7.50 | $285.00 | $270.00 |
The largest size is the cheapest per milligram. Try the calculator →
What the published trials show
GLP-3RT is listed under the research code LY3437943, the molecule known in the literature as retatrutide. Its human data is recent and still growing.
| Study | Who | Length | Average weight change (top dose) | Placebo |
|---|---|---|---|---|
| Phase 2 (NEJM 2023) | 338 adults with obesity | 48 weeks | -24.2% | -2.1% |
| TRIUMPH-2 (topline, July 2026) | 1,152 adults with type 2 diabetes | 80 weeks | -20.8% | -4.0% |
| TRIUMPH-3 (topline, July 2026) | 1,949 adults with severe obesity and heart disease | 80 weeks | -22.6% | -3.2% |
The developer has said it plans to file with the FDA in the first quarter of 2027. Until a decision, the molecule is investigational and not approved anywhere.
Reported side effects
Mostly digestive and dose-related: nausea, diarrhea, vomiting and reduced appetite. In TRIUMPH-3, diarrhea was reported by 24.4% of the 12 mg group against 8.7% on placebo, and 13.5% stopped because of side effects against 4.8% on placebo. Altered skin sensation (dysesthesia) was reported by about 6% on the drug against 1.3% on placebo.
How it compares
| GLP-3RT Vial | GLP-2T Vial | |
|---|---|---|
| Receptors | GLP-1, GIP, glucagon | GLP-1, GIP |
| From | $100.00 | $76.00 |
| Editorial score | 4.8/5 | 4.7/5 |
Full GLP-3RT vs GLP-2T comparison →
Customer reviews
No verified customer reviews have been published for this product yet. Ordered it? Send us your review and we will publish it here with your permission.
FAQ
What is GLP-3RT?
GLP-3RT is a triple agonist acting on GLP-1, GIP and glucagon receptors sold by US Peptide Labs as a research compound in a lyophilized 10 mL vial format.
How much does GLP-3RT Vial cost?
Prices at our last check: 10 mg for $100.00, 20 mg for $170.00, 40 mg for $300.00.
Does it come with a certificate of analysis?
Yes. US Peptide Labs publishes lot-specific COAs from an independent lab, AxisPharm, and prints a QR code on each vial that opens the certificate for that lot.
Is GLP-3RT FDA approved?
No. It is a research chemical sold for laboratory use only and is not approved to diagnose, treat, cure or prevent any disease.
Where does it ship from?
From a US facility with tracking. Orders of $70 or more ship free, and they do not pass through customs.